The United States is currently at the forefront of a revolution in metabolic health, largely driven by the ongoing research and expanding applications of GLP-1 (glucagon-like peptide-1) receptor agonists. These groundbreaking medications, initially developed for type 2 diabetes, have truly transformed the treatment landscape for a range of conditions.
Originally, GLP-1s like Ozempic and Trulicity demonstrated remarkable efficacy in improving blood sugar control by stimulating insulin release, suppressing glucagon, and slowing gastric emptying. However, a significant “side effect” quickly became apparent: substantial weight loss. This discovery led to the approval of higher-dose formulations like Wegovy and Zepbound specifically for chronic weight management, offering a powerful new tool for individuals struggling with obesity. Beyond just shedding weight, these medications have shown significant benefits in improving associated metabolic conditions, including reducing blood pressure, cholesterol levels, and the risk of major cardiovascular events.
The research into GLP-1s is far from over and is currently heading in exciting new directions. Scientists are exploring their potential far beyond diabetes and weight loss. Key areas of ongoing investigation in the U.S. include:
- Expanded Indications: GLP-1s are being rigorously studied for conditions such as chronic kidney disease (with Ozempic under FDA review for this), heart failure with preserved ejection fraction (HFpEF), and metabolic dysfunction-associated steatohepatitis (MASH), a severe form of fatty liver disease.
- Next-Generation Compounds: Researchers are developing novel GLP-1 therapies, including dual and triple agonists that target other hormones like GIP (glucose-dependent insulinotropic polypeptide) and amylin. Compounds like tirzepatide (a dual GLP-1/GIP agonist) have already shown even greater weight loss and glycemic control, while combinations like CagriSema (semaglutide with cagrilintide, an amylin analog) are demonstrating impressive results in clinical trials.
- Oral Formulations: While most current GLP-1s are injectables, the development of effective oral versions like Rybelsus and others in the pipeline could significantly improve patient accessibility and adherence.
- Novel Therapeutic Areas: Emerging research is even investigating GLP-1s for conditions as diverse as early Alzheimer’s disease, polycystic ovary syndrome (PCOS), and certain substance use disorders, hinting at a much broader impact on human health.
On August 15th, the FDA approved the first treatment for MASH, a serious liver disease. At Clinical Research Fastrack, we’re proud to be connected to this groundbreaking milestone.
Before joining us as Director of Education, Genielle served as a lead on several GLP-1 trials—including the very study that resulted in this approval. Today, she brings that same real-world expertise into our classrooms, mentoring and training the next generation of clinical researchers. You can watch her interview where she discusses this experience, here.
Even more exciting: our graduates are now working on these very same trials, playing a hands-on role in advancing the science behind one of the most important medical breakthroughs of our time.
The widespread adoption of GLP-1s also highlights ongoing research into long-term side effects, patient access, and affordability. As these medications redefine treatment paradigms for chronic diseases, the future of GLP-1 research in the U.S. promises continued innovation — and through Fastrack’s training, a pipeline of skilled professionals ready to help drive it forward.
If you’re ready, Schedule your advising appointment now!
Or DM us on Instagram, Facebook, TikTok, or LinkedIn to learn more about our programs and scholarship opportunities!